Net sales and operating profit saw robust double-digit growth in H1 2026, led by Innovative Medicines and higher NubeqaⓇ royalties. Cash flow and profitability improved significantly, with the outlook for 2026 raised. Key milestones included FDA approvals and new licensing agreements.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.